XML 123 R15.htm IDEA: XBRL DOCUMENT
v3.25.0.1

Stock-Based Compensation | 9 Months Ended | 12 Months Ended
--- | --- | ---
Sep. 30, 2024 | Dec. 31, 2023
Share-Based Payment Arrangement [Abstract] |  |
Stock-Based Compensation | 9. Stock-Based Compensation The Company recorded stock-based compensation expense in the following categories on the accompanying condensed consolidated statements of operations for the periods presented (in thousands): Schedule of Stock-based Compensation Expense
|  | 2024 |  |  | 2023 |
|  | Three Months Ended September 30, |
|  | 2024 |  |  | 2023 |
Cost of revenue |  | $ | 5 |  |  | $ | - |
General and administrative |  |  | 195 |  |  |  | 782 |
Sales and marketing |  |  | 2 |  |  |  | - |
Research and development |  |  | 5 |  |  |  | 16 |
Total stock-based compensation expense |  | $ | 207 |  |  | $ | 798 |
|  | 2024 |  |  | 2023 |
|  | Nine Months Ended September 30, |
|  | 2024 |  |  | 2023 |
Cost of revenue |  | $ | 13 |  |  | $ | - |
General and administrative |  |  | 416 |  |  |  | 1,014 |
Sales and marketing |  |  | 4 |  |  |  | - |
Research and development |  |  | 14 |  |  |  | 432 |
Total stock-based compensation expense |  | $ | 447 |  |  | $ | 1,446 |
Equity incentive plan – summary During 2023, the Company adopted the OneMedNet Corporation 2022 Equity Incentive Plan (the “2022 Plan”) and reserved an amount of shares of Common Stock equal to 10% of the number of shares of Common Stock of the Company following the Business Combination for issuance thereunder. The 2022 Plan became effective immediately upon the closing of the Business Combination and replaced the Legacy ONMD equity incentive plan. Equity incentive plan – stock options For the three months ended September 30, 2024 and 2023, the Company recorded stock-based compensation expense of $0 and $0.1 million, respectively, on its outstanding stock options. For the nine months ended September 30, 2024 and 2023, the Company recorded stock-based compensation expense of $34 thousand and $0.3 million, respectively, on its outstanding stock options. Equity incentive plan – restricted stock units (“RSU”) For the three months ended September 30, 2024 and 2023, the Company recorded stock-based compensation expense of $0.2 million and $0.7 million, respectively, on its outstanding restricted stock units. For the nine months ended September 30, 2024 and 2023, the Company recorded stock-based compensation expense of $1.1 million and $0.4 million, respectively, on its outstanding restricted stock units. | 9. Stock Based Compensation Stock-Based Compensation Stock Options During 2020, the Company adopted an equity incentive plan (the “2020 Plan”), which provided for the granting of incentive and nonqualified stock options to employees, directors, and consultants of Legacy ONMD. As of December 31, 2020, the Company had reserved 3,000,000 shares of common stock under the 2020 Plan. Under the 2020 Plan, option awards were generally granted with an exercise price equal to the fair market value of the Company’s stock at the date of grant; those option awards generally vested with a range of one to four years of continuous service and had ten-year contractual terms. Certain option awards provided for accelerated vesting if there was a change in control, as defined in the 2020 Plan. The 2020 Plan also permitted the granting of restricted stock and other stock-based awards. Unexercised options were cancelled upon termination of employment and became available for reissuance under the 2020 Plan. At the Special Meeting held on October 17, 2023, Data Knights shareholders considered and approved the OneMedNet Corporation 2022 Equity Incentive Plan (the “2022 Plan”) and reserved an amount of shares of Common Stock equal to 10% of the number of shares of Common Stock of OneMedNet following the Business Combination for issuance thereunder. The 2022 Plan was approved by the Legacy ONMD Board of Directors on October 17, 2023. The 2022 Plan became effective immediately upon the Closing of the Business Combination and replaced the 2020 Plan. Information with respect to options outstanding is summarized as follows: Schedule of Options Outstanding
|  |  |  |  | Weighted |  |  | Aggregate |
|  | Number of |  |  | Average |  |  | Intrinsic |
|  | Options |  |  | Exercise Price |  |  | Value |
Outstanding as of December 31, 2021 |  |  | 728,603 |  |  | $ | 1.00 |  |  | $ | - |
Granted |  |  | 511,440 |  |  |  | 1.00 |  |  |  |  |
Exercised |  |  | (6,648 | ) |  |  | 1.00 |  |  |  |  |
Cancelled |  |  | (319,539 | ) |  |  | 1.00 |  |  |  |  |
Outstanding as of December 31, 2022 |  |  | 913,856 |  |  | $ | 1.00 |  |  | $ | 3,199 |
Exercised |  |  | (613,510 | ) |  |  | 1.00 |  |  |  |  |
Cancelled |  |  | (300,346 | ) |  |  | 1.00 |  |  |  |  |
Outstanding as of December 31, 2023 |  |  | - |  |  | $ | - |  |  | $ | - |
Vested and exercisable as of December 31, 2023 |  |  | - |  |  |  | - |  |  | $ | - |
For the years ended December 31, 2023 and 2022, the Company recorded stock-based compensation expense of $0.4 million and $0.3 million, respectively, on its outstanding stock options. The Company has determined its share-based payments to be a Level 3 fair value measurement. For the year ended December 31, 2023 and 2022, the Company has used the Black-Scholes option pricing model and estimated no expected dividends and the following weighted average assumptions: Schedule of Fair Value of Stock Options
|  | For the year ended December 31, |
|  | 2023 |  |  | 2022 |
Risk-free interest rate |  |  | - |  |  |  | 0.73% - 2.96 | %
Expected dividend yield |  |  | - |  |  |  | - |
Expected term in years |  |  | - |  |  |  | 1.36 - 1.85 |
Expected volatility |  |  | - |  |  |  | 50.0% - 86.3 | %
On November 7, 2023, as part of the Business Combination, the 2020 Plan was cancelled and all vested shares were exercised and converted at the appropriate conversion ratio to Common Stock of the Company. The Company issued shares of Common Stock of 543,057 which represents 613,510 vested options less an exercise price of $1.00. Restricted Stock Awards Certain employees, directors and consultants have been awarded restricted stock. The restricted stock vesting consists of milestone and time-based vesting as well as compensation for services performed by the Board of Directors. The following table summarizes restricted stock award activity for the years ended December 31, 2023 and 2022: Schedule of Restricted Stock Award Activity
|  |  |  |  | Weighted |
|  | Number of |  |  | Average Grant |
|  | Awards |  |  | Date Fair Value |
Nonvested as of December 31, 2021 |  |  | - |  |  | $ | - |
Granted |  |  | 354,551 |  |  |  | 4.80 |
Vested |  |  | (177,276 | ) |  |  | 4.80 |
Nonvested as of December 31, 2022 |  |  | 177,275 |  |  | $ | 1.48 |
Granted |  |  | 88,639 |  |  |  | 7.21 |
Vested |  |  | (265,914 | ) |  |  | 5.60 |
Nonvested as of December 31, 2023 |  |  | - |  |  | $ | - |
The total fair value of the Company’s previous stock awards vested during the years ended December 31, 2023 and 2022 was $1.1 million and $1.5 million, respectively. On November 7, 2023, as part of the Business Combination, all vested shares were exercised and converted at the appropriate conversion ratio to Common Stock of the Company. The Company recorded stock-based compensation expense in the following categories on the accompanying consolidated statements of operations for the periods presented (in thousands): Schedule of Stock-based Compensation Expense
|  | 2023 |  |  | 2022 |
|  | For the year ended December 31, |
|  | 2023 |  |  | 2022 |
Research and development |  | $ | 434 |  |  | $ | 638 |
General and administrative |  |  | 1,041 |  |  |  | 1,227 |
Total stock-based compensation expense |  | $ | 1,475 |  |  | $ | 1,865 |

X
- Definition The entire disclosure for share-based payment arrangement. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/718/tableOfContent Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (l) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration